… The epidermal growth factor receptor (EGFR) plays a pivotal … the EGFR inhibitor (Ne) [128].
Interestingly, NBSNe inhibited tumor … A chitosan derivative for targeting EGFR-overexpressing …

… epidermal growth factor receptor (EGFR) mutations respond well to osimertinib (AZD9291),
a third-generation, mutation-selective EGFR inhibitor. The … patient-derived xenografts would …

… therapy such as tyrosine kinase inhibitor for Epidermal Growth Factor Receptor (EGFR), …
(E884K) that may reduce sensitivity to different EGFR inhibitors [72]. Several mutations at the …

… therapy targeting the epidermal growth factor receptor (EGFR… collectively encounter EGFR
inhibition during cetuximab treatment. … that cetuximab treatment causes patient-derived CAFs …

… derived xenograft (PDX) tumours from four different patients who had developed resistance
to first-line or second-line therapy with EGFR inhibitors … activated when growth factors are …

… mutations of epidermal growth factor receptor (EGFR) are the … may derive more benefit from
a combination treatment with … -generation TKIs can restore EGFR inhibition. To date, clinical …

… EGFR transactivation. We proposed administering erlotinib hydrochloride, an EGFR inhibitor,
to treat 3 … informed consent was obtained from the patients’ parents prior to starting therapy. …

… impact of the epidermal growth factor receptor (EGFR) on the … and selective anti-EGFR
inhibitors, particularly monoclonal … contrast of NIRF signals was obtained between HCT-116 …

… and EGFR inhibition represent a rational combination strategy for EGFR-mutant NSCLC
treatment. In … Nintedanib inhibits fibroblast growth factor receptor, PDGF receptor, and VEGFR. …

… drug for the treatment of patients who have NSCLC with activating EGFR mutations (…
epidermal growth factor receptor tyrosine kinase inhibitors. Osimertinib-resistant cell lines derived …